title: Effect of dexmedetomidine on erythrocyte deformability during ischaemia-reperfusion injury of heart in diabetic rats.
abstract: The aim of this study is to evaluate the effect of dexmedetomidine on erythrocyte deformability during IR heart injury in diabetic rats.
  
  
  METHODS
  Eighteen Wistar Albino rats were included in the study after streptozocin (55 mg/kg) treatment for four weeks. In the Group C and DC (sham-control group), the coronary artery was not occluded or reperfused in the control rats. In the Group DIR, a branch of the left coronary artery was occluded for 30 minutes followed by two hours of reperfusion to produce IR. In the Group DIRD, a branch of the left coronary artery was occluded for 30 minutes followed by two hours of reperfusion to produce IR, and dexmedetomidine was administrated via 100 µg/kg IP route 30 minutes before ligating the left coronary artery. Deformability measurements were performed in erythrocyte suspensions containing Htc 5 % in a PBS buffer.
  
  
  RESULTS
  The deformability index was significantly increased in diabetic rats; however, it was similar in the Group DC and DIRD. It was significantly increased in the Group DIR when compared to the Group C, DIRD and DC. The relative resistance was increased in IR models.
  
  
  CONCLUSIONS
  Erythrocyte deformability was decreased in rats having diabetes and IR injury. This injury might lead to further problems in microcirculation. It was shown that dexmedetomidine might be useful in enhancing the adverse effects of this type of injury (Fig. 1, Ref. 39).
authors.forename: M
authors.initials: M
authors.lastname: Arslan
authors.forename: F M
authors.initials: FM
authors.lastname: Comu
authors.forename: G
authors.initials: G
authors.lastname: Kip
authors.forename: M
authors.initials: M
authors.lastname: Alkan
authors.forename: H A
authors.initials: HA
authors.lastname: Kiraz
authors.forename: A
authors.initials: A
authors.lastname: Ozer
authors.forename: V
authors.initials: V
authors.lastname: Sivgin
mesh_terms: D058647:Adrenergic alpha-2 Receptor Agonists / Q000494:pharmacology*; D000818:Animals; D020927:Dexmedetomidine / Q000494:pharmacology*; D003921:Diabetes Mellitus, Experimental / Q000097:blood* / Q000150:complications; D004195:Disease Models, Animal; D004907:Erythrocyte Deformability / Q000187:drug effects*; D008297:Male; D015428:Myocardial Reperfusion Injury / Q000097:blood* / Q000150:complications; D017208:Rats, Wistar
chemical_list: D058647:Adrenergic alpha-2 Receptor Agonists; D020927:Dexmedetomidine